ICVTS Click here to go to Siemens website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Interact CardioVasc Thorac Surg 2007;6:297. doi:10.1510/icvts.2006.144014A
© 2007 European Association of Cardio-Thoracic Surgery
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kan, C.-D.
Right arrow Articles by Lee, H.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kan, C.-D.
Right arrow Articles by Lee, H.-L.
Related Collections
Right arrowRelated Article

Institutional report - Experimental

ICVTS on-line discussion A Equivocal results for cytokine therapy

Chung-Dann Kan and Hsin-Ling Lee

Department of Surgery, National Cheng Kung University Hospital, Tainan 70124, Taiwan

Can erythropoietin improve skeletal myoblast engraftment in infarcted myocardium?

eComment: Cell transplantation therapy is a novel modality for endstage ischemic heart. In preclinical experiments and clinical practices, it has been proved to be an effective therapy. However, the key point for its use depends on the cell types, delivery methods, and the cell survival rates. More and more papers advocate multi-strategies for increasing the cell survival rates in-vivo. Cytokine therapy, especially erythropoietin, is also a good combination modality. Although this paper is a negative finding for the cell survival-enhancing strategies, it provides more questions for the timing, dosing, and combination strategies to testify [1].


   Reference
Top
 Reference
 

  1. Chanséaume S, Azarnoush K, Maurel A, Bellamy V, Peyrard S, Bruneval P, Hagege AA, Menasché P. Can erythropoietin improve skeletal myoblast engraftment in infarcted myocardium? Interact CardioVasc Thorac Surg 2007; 6:293–297.[Abstract/Free Full Text]

Related Article

Can erythropoietin improve skeletal myoblast engraftment in infarcted myocardium?
Sylvain Chanséaume, Kasra Azarnoush, Agnès Maurel, Valérie Bellamy, Séverine Peyrard, Patrick Bruneval, Albert A. Hagège, and Philippe Menasché
Interactive CardioVascular and Thoracic Surgery 2007 6: 293-297. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kan, C.-D.
Right arrow Articles by Lee, H.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kan, C.-D.
Right arrow Articles by Lee, H.-L.
Related Collections
Right arrowRelated Article

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS